Bone Morphogenetic Protein 4 is one of the BMPs, some of which belong to the TGF-beta superfamily (BMP2-7). There are more than thirteen BMPs have been discovered nowadays and they are involved in inducing cartilage and bone formation. BMP-4 is expressed in the lung and lower levels seen in the kidney. It also presents in normal and neoplastic prostate tissues, and prostate cancer cell lines. It regulates the formation of teeth, limbs and bone from mesoderm. Furthermore it also plays a role in fracture repair. BMP-4 signals through tetrameric complexes composed of type I and type II receptors and regulates it function by interaction with multiple proteins and glycosaminoglycans. The human BMP-4 shares 98 % sequence indentity with mouse BMP-4. Reduced expression of BMP-4 is associated with a number of bone diseases, including the heritable disorder Fibrodysplasia Ossificans Progressiva.
Source
Escherichia coli.
Molecular Weight
Approximately 13.3 kDa, a monomeric, non-glycosylated polypeptide chain containing 117 amino acids.
Biological Activity
No data available
Appearance
Sterile filtered white lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2 um filtered concentrated solution in 50 mM Na2CO3, 5 mM DTT, pH 11.0.
Endotoxin
Less than 1 EU/ug of rHuBMP-4 as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
